Charles River Laboratories (CRL) Tops Q1 EPS by 8c; Boosts Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $345.37 +1.68%
Revenue Growth %: -4.0%
Financial Fact:
Other, net: 1.02M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -4.0%
Financial Fact:
Other, net: 1.02M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $0.82, $0.08 better than the analyst estimate of $0.74. Revenue for the quarter came in at $299.4 million versus the consensus estimate of $302.08 million.
Charles River Laboratories sees FY2014 EPS of $3.15 - $3.25, versus prior guidance of $.00 - $3.10. Sees sales growth of 9 to 11 percent, from 3 to 5 percent prior.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI-powered cyber threats light a fire under cybersecurity stocks
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
